RSV Archives

TAG:

RSV

Despite COVID-19 Losses, IVD Executives Remain Upbeat

By Donna Marie Pocius | From the Volume XXX, No. 8 – May 30, 2023 Issue

Continuing declines in COVID-19 test revenues was a common theme during the first quarte…

IVD Firms Prepare for OTC, Home Test Market Expansion

By Robert Michel | From the Volume XXX, No. 6 – April 17, 2023 Issue

CEO SUMMARY: With public interest in home testing growing, some IVD manufacturers are preparing to serve a fast-expanding market for over-the-counter and at-home tests. IVD firms are banking on the…

Public IVD Companies Report Q4, Full-Year 2022 Earnings

By Robert Michel | From the Volume XXX No. 3 – February 13, 2023 Issue

YEAR-END AND Q4 EARNINGS REPORTS FROM MAJOR IN VITRO DIAGNOSTICS (IVD) COMPANIES pointed to a welcome sign of core diagnostic business rebounding. That’s the good news for IVD firms. The bad news? All of the SARS-CoV-2 testing revenue that th…

Two Positive Messages to Focus on at Year’s End

By R. Lewis Dark | From the Volume XXIX, No. 17 – December 12, 2022 Issue

Clinical laboratory managers and anatomic pathologists are winding down another tumultuous year for the healthcare industry. It was a year marked by unexpected twists and turns. It was also a year marked by two positive developments for labs. First, the…

Top Public IVD Companies Report Q3/Q4 2022 Earnings

By Robert Michel | From the Volume XXIX, No. 17 – December 12, 2022 Issue

IT WAS A MIXED BAG OF THIRD QUARTER FINANCIAL RESULTS for the nation’s largest in vitro diagnostics (IVD) manufacturers, with COVID-19 testing volume a contributing factor. Fluctuating demand for SARS-CoV-2 testing proved perplexing, as some IV…

October 31, 2022, Intelligence: Late-Breaking Lab News

By Robert Michel | From the Volume XXIX, No. 15 – October 31, 2022 Issue

Clinical laboratories may soon face increasing pressure to test for respiratory syncytial virus (RSV) now that the public has become aware of the pathogen. Over the past month, there has been an onslaught of media attention on RSV. The coverage has often focused on how this common virus could tag…

Volume XXXI, No. 12 – September 3, 2024

This special intelligence briefing—presented in three parts—identifies the factors retarding a faster adoption of digital pathology. Also, how to protect your lab’s proprietary LDTs and assess the financial impact of compliance.

See the full table of contents

How Much Laboratory Business Intelligence Have You Missed?

Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!

Need A Group Membership? Company Discounts are Available!

Sign up for TDR Insider

Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.

Topics

Visit The Dark Library